Edward Faught

Edward Faught

Auto-generated profile, based on publicly available information

Edward Faught

Neurology, Emory University, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Epilepsy Currents
Verified
Journal Article
Open access
PDF file
DVDavid G. Vossler
David G. Vossler
JBJacquelyn L. Bainbridge
Jacquelyn L. Bainbridge
JBJane G. Boggs
Jane G. Boggs
ENEdward J. Novotny
Edward J. Novotny
TLTobias Loddenkemper
Tobias Loddenkemper
TWTimothy E. Welty
Timothy E. Welty
Purpose: Established tonic–clonic status epilepticus (SE) does not stop in one-third of patients when treated with an intravenous (IV) benzodiazepine bolus followed by a loading dose of a second antiseizure medication (ASM). These patients have refractory status epilepticus (RSE) and a high risk of morbidity and death. For patients with convulsive refractory status epilepticus (CRSE), we sought to determine the strength of evidence for 8 parenteral ASMs used as third-line treatment in stopping clinical CRSE. Methods: A structured literature search (MEDLINE, Embase, CENTRAL, CINAHL) was performed to identify original studies on the treatment of CRSE in children and adults using IV brivaracetam, ketamine, lacosamide, levetiracetam (LEV), midazolam (MDZ), pentobarbital (PTB; and thiopental), propofol (PRO), and valproic acid (VPA). Adrenocorticotropic hormone (ACTH), corticosteroids, intravenous immunoglobulin (IVIg), magnesium sulfate, and pyridoxine were added to determine the effectiveness in treating hard-to-control seizures in special circumstances. Studies were evaluated by predefined criteria and were classified by strength of evidence in stopping clinical CRSE (either as the last ASM added or compared to another ASM) according to the 2017 American Academy of Neurology process. Results: No studies exist on the use of ACTH, corticosteroids, or IVIg for the treatment of CRSE. Small series and case reports exist on the use of these agents in the treatment of RSE of suspected immune etiology, severe epileptic encephalopathies, and rare epilepsy syndromes. For adults with CRSE, insufficient evidence exists on the effectiveness of brivaracetam (level U; 4 class IV studies). For children and adults with CRSE, insufficient evidence exists on the effectiveness of ketamine (level U; 25 class IV studies). For children and adults with CRSE, it is possible that lacosamide is effective at stopping RSE (level C; 2 class III, 14 class IV studies). For children with CRSE, insufficient evidence exists that LEV and VPA are equally effective (level U, 1 class III study). For adults with CRSE, insufficient evidence exists to support the effectiveness of LEV (level U; 2 class IV studies). Magnesium sulfate may be effective in the treatment of eclampsia, but there are only case reports of its use for CRSE. For children with CRSE, insufficient evidence exists to support either that MDZ and diazepam infusions are equally effective (level U; 1 class III study) or that MDZ infusion and PTB are equally effective (level U; 1 class III study). For adults with CRSE, insufficient evidence exists to support either that MDZ infusion and PRO are equally effective (level U; 1 class III study) or that low-dose and high-dose MDZ infusions are equally effective (level U; 1 class III study). For children and adults with CRSE, insufficient evidence exists to support that MDZ is effective as the last drug added (level U; 29 class IV studies). For adults with CRSE, insufficient evidence exists to support that PTB and PRO are equally effective (level U; 1 class III study). For adults and children with CRSE, insufficient evidence exists to support that PTB is effective as the last ASM added (level U; 42 class IV studies). For CRSE, insufficient evidence exists to support that PRO is effective as the last ASM used (level U; 26 class IV studies). No pediatric-only studies exist on the use of PRO for CRSE, and many guidelines do not recommend its use in children aged <16 years. Pyridoxine-dependent and pyridoxine-responsive epilepsies should be considered in children presenting between birth and age 3 years with refractory seizures and no imaging lesion or other acquired cause of seizures. For children with CRSE, insufficient evidence exists that VPA and diazepam infusion are equally effective (level U, 1 class III study). No class I to III studies have been reported in adults treated with VPA for CRSE. In comparison, for children and adults with established convulsive SE (ie, not RSE), after an initial benzodiazepine, it is likely that loading doses of LEV 60 mg/kg, VPA 40 mg/kg, and fosphenytoin 20 mg PE/kg are equally effective at stopping SE (level B, 1 class I study). Conclusions: Mostly insufficient evidence exists on the efficacy of stopping clinical CRSE using brivaracetam, lacosamide, LEV, valproate, ketamine, MDZ, PTB, and PRO either as the last ASM or compared to others of these drugs. Adrenocorticotropic hormone, IVIg, corticosteroids, magnesium sulfate, and pyridoxine have been used in special situations but have not been studied for CRSE. For the treatment of established convulsive SE (ie, not RSE), LEV, VPA, and fosphenytoin are likely equally effective, but whether this is also true for CRSE is unknown. Triple-masked, randomized controlled trials are needed to compare the effectiveness of parenteral anesthetizing and nonanesthetizing ASMs in the treatment of CRSE.

1 November 2012 in Epilepsy & Behavior
Verified
Journal Article
Closed access
EFEdward Faught
Edward Faught

10 January 2023 in Epilepsia
Verified
Journal Article
Closed access
EBEttore Beghi
Ettore Beghi
GGGiorgia Giussani
Giorgia Giussani
CCCinzia Costa
Cinzia Costa
JDJacopo C. DiFrancesco
Jacopo C. DiFrancesco
MDMonica Dhakar
Monica Dhakar
T(The Ilae Task Force On Epilepsy In The Elderly (2017–2021)
The Ilae Task Force On Epilepsy In The Elderly (2017–2021)

20 October 2022 in Epilepsia
Verified
Journal Article
Open access
LPLoretta Piccenna
Loretta Piccenna
RORebecca O'DWyer
Rebecca O'DWyer
ILIlo Leppik
Ilo Leppik
EBEttore Beghi
Ettore Beghi
GGGiorgia Giussani
Giorgia Giussani
Patrick KwanPatrick Kwan
Patrick Kwan
Older adults represent a highly heterogeneous population, with multiple diverse subgroups. Therefore, an individualized approach to treatment is essential to meet the needs of each unique subgroup. Most comparative studies focusing on treatment of epilepsy in older adults have found that levetiracetam has the best chance of long‐term seizure freedom. However, there is a lack of studies investigating other newer generation antiseizure medications (ASMs). Although a number of randomized clinical trials have been performed on older adults with epilepsy, the number of participants studied was generally small, and they only investigated short‐term efficacy and tolerability. Quality of life as an outcome is often missing but is necessary to understand the effectiveness and possible side effects of treatment. Prognosis needs to move beyond the focus on seizure control to long‐term patient‐centered outcomes. Dosing studies with newer generation ASMs are needed to understand which treatments are the best in the older adults with different comorbidities. In particular, more high‐level evidence is required for older adults with Alzheimer's disease with epilepsy and status epilepticus. Future treatment studies should use greater homogeneity in the inclusion criteria to allow for clearer findings that can be comparable with other studies to build the existing treatment evidence base.

1 August 2018 in Epilepsy & Behavior
Verified
Journal Article
Closed access
EFEdward Faught
Edward Faught
SHSandra Helmers
Sandra Helmers
DTDavid Thurman
David Thurman
HKHyunmi Kim
Hyunmi Kim
LKLinda Kalilani
Linda Kalilani

13 January 2016 in Epilepsy & Behavior
Verified
Journal Article
Open access
PDF file
SGShaloo Gupta
Shaloo Gupta
Patrick KwanPatrick Kwan
Patrick Kwan
EFEdward Faught
Edward Faught
WTWan Tsong
Wan Tsong
AFAnna Forsythe
Anna Forsythe
PRPhillipe Ryvlin
Phillipe Ryvlin
• Idiopathic generalized epilepsy (IGE) outcomes were examined by seizure frequency. • Quality of life, health utilities, productivity, resource use, & cost were outcomes. • Over 40% reported persistent seizures (≥ <!----> 1 per year) in the US, 5EU, and Brazil. • Overall, higher seizure frequency was associated with worse outcomes. • Decreasing seizure frequency may proportionally reduce the burden attributed to IGE.